Phase 1 Evaluation of [(64)Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors.
Mol Imaging Biol
; 18(3): 446-53, 2016 06.
Article
in En
| MEDLINE
| ID: mdl-26567113
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Organometallic Compounds
/
Radiometry
/
Antibodies, Neutralizing
/
Antibodies, Monoclonal
/
Neoplasms
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Mol Imaging Biol
Journal subject:
BIOLOGIA MOLECULAR
/
DIAGNOSTICO POR IMAGEM
Year:
2016
Document type:
Article
Affiliation country:
Estados Unidos
Country of publication:
Estados Unidos